metoprolol gase pH and PaCO2 were unaltered; mean PaO2 increased by 12.2 +/- 5.8 torr (p<0.05) B indicates blood pressure; bpm, beats per minute; MAT, multifocal atrial tachycardia; N/A, not applicable; NSR, normal sinus rhythm; PaCO2, partial pressure of carbon dioxide; pt, patient; and w/, with. Data Supplement 9. Randomized Trials Comparing Atrioventricular Nodal Re-Entrant Tachycardia Section 5 – Study Aim of Study Study Study Pt Population Endpoints P Values, OR: HR: Study Name, Study Type Intervention Comparator RR: & 95% CI: Limitations Author, (Size, Group (n) Group (n) & Adverse Year N) Events Inclusion Criteria Exclusion Criteria Primary Safety Secondary Endpoint Endpoint Endpoint (efficacy) and Results and and Results Results Pharmacological Therapy Waxman Effective 50 Group 1 N/A PSVT w/ AF, atrial N/A Control of N/A N/A N/A Verapamil HL of (n=20) w/ AF flutter, PSVT ventricular results in a 1981 IV or flutter response in clinically (112) group 1, significant Group 2 restoration of slowing of the (n=30) sinus rhythm ventricular PSVT in group 2 response in (AVNRT in 8 AF or atrial pts), In Group 1 flutter and is low-dose superior to verapamil placebo for (0.075 mg/kg conversion of body weight) PSVT to sinus decreased the rhythm mean ventricular rate from 146 to 114 bpm (p<0.01) compared to a decrease of 145 to 132 bpm (p<0.01) after placebo. In Group 2, 14/29 pts converted to sinus rhythm after low-dose verapamil,
metoprolol gase pH and PaCO2 were unaltered; mean PaO2 increased by 12.2 +/- 5.8 torr (p<0.05) B indicates blood pressure; bpm, beats per minute; MAT, multifocal atrial tachycardia; N/A, not applicable; NSR, normal sinus rhythm; PaCO2, partial pressure of carbon dioxide; pt, patient; and w/, with. Data Supplement 9. Randomized Trials Comparing Atrioventricular Nodal Re-Entrant Tachycardia – Section 5 Study Name, Author, Year Aim of Study Study Type (Size, N) Study Intervention Group (n) Study Comparator Group (n) Pt Population Endpoints P Values, OR: HR: RR: & 95% CI: Study Limitations & Adverse Events Inclusion Criteria Exclusion Criteria Primary Endpoint (efficacy) and Results Safety Endpoint and Results Secondary Endpoint and Results Pharmacological Therapy Waxman HL 1981 (112) of IV 50 Group 1 (n=20) w/ AF or flutter Group 2 (n=30) PSVT (AVNRT in 8 pts), N/A PSVT w/ AF, atrial flutter, PSVT N/A Control of ventricular response in group 1, restoration of sinus rhythm in group 2 In Group 1 low-dose verapamil (0.075 mg/kg body weight) decreased the mean ventricular rate from 146 to 114 bpm (p<0.01) compared to a decrease of 145 to 132 bpm (p<0.01) after placebo. In Group 2, 14/29 pts converted to sinus rhythm after low-dose verapamil, N/A N/A N/A Verapamil results in a clinically significant slowing of the ventricular response in AF or atrial flutter and is superior to placebo for conversion of PSVT to sinus rhythm Effective
2015_SVT_Evidence_Tables_Data_Supplement.docx